[Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting]

Rev Mal Respir. 2004 Nov;21(5 Pt 1):881-5. doi: 10.1016/s0761-8425(04)71466-7.
[Article in French]
No abstract available

Publication types

  • Editorial
  • Review

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / genetics*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Epidermal Growth Factor / antagonists & inhibitors
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / genetics
  • Gefitinib
  • Genes, erbB-1
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics*
  • Mutation
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Proto-Oncogene Proteins c-raf / genetics
  • Quinazolines / pharmacology
  • Quinazolines / therapeutic use*

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Epidermal Growth Factor
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • Proto-Oncogene Proteins c-raf
  • Gefitinib